Key Insights

Highlights

Success Rate

73% trial completion

Published Results

29 trials with published results (24%)

Research Maturity

63 completed trials (52% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

18.9%

23 terminated out of 122 trials

Success Rate

73.3%

-13.3% vs benchmark

Late-Stage Pipeline

7%

9 trials in Phase 3/4

Results Transparency

46%

29 of 63 completed with results

Key Signals

29 with results73% success23 terminated

Data Visualizations

Phase Distribution

105Total
Not Applicable (4)
Early P 1 (2)
P 1 (60)
P 2 (30)
P 3 (8)
P 4 (1)

Trial Status

Completed63
Terminated23
Recruiting12
Unknown9
Active Not Recruiting7
Withdrawn6

Trial Success Rate

73.3%

Benchmark: 86.5%

Based on 63 completed trials

Clinical Trials (122)

Showing 20 of 20 trials
NCT03180502Phase 2Active Not RecruitingPrimary

Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma

NCT03581292Phase 2Active Not RecruitingPrimary

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

NCT03919071Phase 2Active Not RecruitingPrimary

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

NCT03975829Phase 4Active Not Recruiting

Pediatric Long-Term Follow-up and Rollover Study

NCT06333899Early Phase 1Recruiting

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

NCT05839379Recruiting

Targeted Pediatric High-Grade Glioma Therapy

NCT04780009Recruiting

Loupe-Based Intraoperative Fluorescence Imaging

NCT04978727Phase 1Active Not Recruiting

A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

NCT01386710Phase 1Suspended

Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma

NCT01269853Phase 1Recruiting

Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

NCT05843253Phase 2Recruiting

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

NCT06264388Phase 2Recruiting

DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma

NCT04105374Phase 2WithdrawnPrimary

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

NCT06108206Active Not Recruiting

Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma

NCT05934630TerminatedPrimary

Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors

NCT05698524Phase 1Recruiting

A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma

NCT02800486Phase 2Recruiting

Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

NCT03603405Phase 1Recruiting

HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM

NCT07448480Active Not Recruiting

Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas

NCT05084430Phase 1Recruiting

Study of Pembrolizumab and M032 (NSC 733972)

Scroll to load more

Research Network

Activity Timeline